

# CAR T cells: continuation in a revolution of immunother

Lancet Oncology, The  
21, e168-e178

DOI: [10.1016/s1470-2045\(19\)30823-x](https://doi.org/10.1016/s1470-2045(19)30823-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. <i>Lancet Oncology</i> , The, 2020, 21, e477-e487.	10.7	57
2	Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. <i>Frontiers in Immunology</i> , 2020, 11, 2100.	4.8	57
3	Immune escape: A critical hallmark in solid tumors. <i>Life Sciences</i> , 2020, 258, 118110.	4.3	91
4	A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate. <i>Science Advances</i> , 2020, 6, eabb9484.	10.3	13
5	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. <i>Seminars in Hematology</i> , 2020, 57, 83-91.	3.4	5
6	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1553-1559.	5.0	16
7	Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. <i>Frontiers in Immunology</i> , 2020, 11, 2044.	4.8	18
8	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020, 12, 1457-1476.	2.1	37
9	Antibody Targeting of Eph Receptors in Cancer. <i>Pharmaceuticals</i> , 2020, 13, 88.	3.8	27
10	A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3886.	4.1	23
11	Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. <i>Cell Proliferation</i> , 2020, 53, e12865.	5.3	43
12	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.8	30
13	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	5.4	10
14	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, .	14.9	13
15	Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 45-59.	8.7	28
16	Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies. <i>Bioanalysis</i> , 2021, 13, 115-128.	1.5	11
17	Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?. <i>Hematological Oncology</i> , 2021, 39, 270-272.	1.7	1
18	Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 124, 359-367.	6.4	590

#	ARTICLE	IF	CITATIONS
19	T cell gene therapy to treat immunodeficiency. <i>British Journal of Haematology</i> , 2021, 192, 433-443.	2.5	11
20	Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma. <i>OncImmunology</i> , 2021, 10, 1983306.	4.6	11
21	Spontaneously occurring canine cancer as a relevant animal model for developing novel treatments for human cancers. <i>Translational and Regulatory Sciences</i> , 2021, 3, 51-59.	0.2	1
22	In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 610042.	4.8	6
23	Novel method for effectively amplifying human peripheral blood T cells in vitro. <i>Experimental Cell Research</i> , 2021, 399, 112451.	2.6	2
24	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. <i>Nature Communications</i> , 2021, 12, 1237.	12.8	29
25	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. <i>Lancet Haematology</i> , 2021, 8, e216-e228.	4.6	41
26	In respond to commensal bacteria: $\hat{I}^3\hat{T}$ cells play a pleiotropic role in tumor immunity. <i>Cell and Bioscience</i> , 2021, 11, 48.	4.8	5
27	Cardiotoxicities of novel cancer immunotherapies. <i>Heart</i> , 2021, 107, 1694-1703.	2.9	42
28	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	4.4	20
29	The landscape of bispecific T cell engager in cancer treatment. <i>Biomarker Research</i> , 2021, 9, 38.	6.8	90
30	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	4.5	93
31	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. <i>Current Medical Science</i> , 2021, 41, 420-430.	1.8	5
32	Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. <i>Frontiers in Veterinary Science</i> , 2021, 8, 672361.	2.2	8
33	Non-viral transfection technologies for next-generation therapeutic T cell engineering. <i>Biotechnology Advances</i> , 2021, 49, 107760.	11.7	33
34	Cell Fate Reprogramming in the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 714822.	4.8	27
35	Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 523-543.	3.8	11
36	Complex dynamics of a tumor-immune system with antigenicity. <i>Applied Mathematics and Computation</i> , 2021, 400, 126052.	2.2	6

#	ARTICLE	IF	CITATIONS
37	Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma. <i>Cancer Medicine</i> , 2021, 10, 7395-7403.	2.8	4
38	Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity. <i>Journal of Neurology</i> , 2022, 269, 609-615.	3.6	12
39	PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. <i>Frontiers in Immunology</i> , 2021, 12, 665970.	4.8	24
40	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. <i>Frontiers in Pharmacology</i> , 2021, 12, 720692.	3.5	20
41	Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. <i>Cancer Cell International</i> , 2021, 21, 450.	4.1	11
42	Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 4540.	3.7	6
43	Targeting immune dysfunction in aging. <i>Ageing Research Reviews</i> , 2021, 70, 101410.	10.9	76
44	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	6.3	29
45	Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism. <i>Advanced Science</i> , 2021, 8, 2101029.	11.2	20
46	Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 702-706.	1.2	2
47	Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 410-430.	4.4	32
48	CAR-T therapy: Prospects in targeting cancer stem cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9891-9904.	3.6	16
49	Implications of Antigen Selection on T Cell-Based Immunotherapy. <i>Pharmaceuticals</i> , 2021, 14, 993.	3.8	6
50	Immune Cycle-Based Strategies for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2107540.	14.9	24
51	Patch grafting, strategies for transplantation of organoids into solid organs such as liver. <i>Biomaterials</i> , 2021, 277, 121067.	11.4	15
52	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. <i>Theranostics</i> , 2021, 11, 3489-3501.	10.0	35
53	Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1897-1909.	3.3	23
54	In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models. <i>Cancers</i> , 2021, 13, 5069.	3.7	4

#	ARTICLE	IF	CITATIONS
55	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 751183.	2.8	10
56	Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. <i>Cancer Letters</i> , 2021, 523, 149-161.	7.2	22
57	Nanotechnology-based products for cancer immunotherapy. <i>Molecular Biology Reports</i> , 2022, 49, 1389-1412.	2.3	7
58	Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. <i>Frontiers in Immunology</i> , 2021, 12, 782775.	4.8	23
60	Revisiting the role of pulsed electric fields in overcoming the barriers to in vivo gene electrotransfer. <i>Bioelectrochemistry</i> , 2022, 144, 107994.	4.6	20
61	Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1549-1567.	4.2	20
62	Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. <i>Radiology</i> , 2022, 302, 438-445.	7.3	9
63	Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. , 2021, 9, e003850.		20
64	Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 253.	2.4	10
66	Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. <i>Cancers</i> , 2022, 14, 645.	3.7	40
67	Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress. <i>Stem Cell Research and Therapy</i> , 2022, 13, 40.	5.5	28
68	Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. <i>Transplant Immunology</i> , 2022, 71, 101538.	1.2	10
69	Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [68Ga]Ga-NOTA-Nb109. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 3300-3313.	2.0	5
70	Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer. <i>Antibody Therapeutics</i> , 2022, 5, 73-83.	1.9	5
71	Polymeric Systems for Cancer Immunotherapy: A Review. <i>Frontiers in Immunology</i> , 2022, 13, 826876.	4.8	12
72	Review article: hepatitis Bâ€”current and emerging therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 805-819.	3.7	13
73	Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. <i>Current Cancer Drug Targets</i> , 2022, 22, 437-453.	1.6	2
74	Pan-Cancer Transcriptome and Immune Infiltration Analyses Reveal the Oncogenic Role of Far Upstream Element-Binding Protein 1 (FUBP1). <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 794715.	3.5	0

#	ARTICLE	IF	CITATIONS
75	A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. <i>Experimental Hematology and Oncology</i> , 2022, 11, 15.	5.0	19
76	Increasing Role of Targeted Immunotherapies in the Treatment of AML. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3304.	4.1	6
77	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. <i>Genes and Diseases</i> , 2023, 10, 1367-1401.	3.4	152
78	Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1392.	3.7	16
79	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 858590.	4.8	4
80	GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 857308.	4.8	28
81	Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism. <i>Oncolmmunology</i> , 2022, 11, 2055703.	4.6	8
82	Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review. <i>Stem Cells International</i> , 2022, 2022, 1-8.	2.5	8
83	Kanser immünoterapisinde gncel yaklaşımlar ve immünoterapinin sınırlayıcı etkilerine genel bakış. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , .	0.4	0
84	Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. <i>Cancer Letters</i> , 2022, 536, 215668.	7.2	11
85	Nanosensors in clinical development of CAR-T cell immunotherapy. <i>Biosensors and Bioelectronics</i> , 2022, 206, 114124.	10.1	5
86	Movement Disorders in Oncology: From Clinical Features to Biomarkers. <i>Biomedicines</i> , 2022, 10, 26.	3.2	5
87	Immunotherapy for anaplastic thyroid carcinoma: the present and future. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2021, 50, 675-684.	0.3	2
88	Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation. <i>Scientific Reports</i> , 2022, 12, 6572.	3.3	5
89	Development of CAR T Cell Therapy in Children—A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2022, 11, 2158.	2.4	12
90	Guiding the global evolution of cytogenetic testing for hematologic malignancies. <i>Blood</i> , 2022, 139, 2273-2284.	1.4	29
92	Engineering $\beta$ T Cells: Recognizing and Activating on Their Own Way. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	12
93	Therapeutic bispecific antibodies against intracellular tumor antigens. <i>Cancer Letters</i> , 2022, 538, 215699.	7.2	12

#	ARTICLE	IF	CITATIONS
94	CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. <i>Cancer Letters</i> , 2022, , 215762.	7.2	4
95	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development. <i>Clinical and Translational Science</i> , 2022, 15, 2057-2074.	3.1	9
96	Single B Cell Gene Co-Expression Networks Implicated in Prognosis, Proliferation, and Therapeutic Responses in Non-Small Cell Lung Cancer Bulk Tumors. <i>Cancers</i> , 2022, 14, 3123.	3.7	5
97	Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination. <i>Biomaterials Science</i> , 2022, 10, 4612-4626.	5.4	2
98	Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells. <i>Cancers</i> , 2022, 14, 3168.	3.7	8
99	The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	9
100	Identification of BST2 Contributing to the Development of Glioblastoma Based on Bioinformatics Analysis. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
101	The role of imaging in targeted delivery of nanomedicine for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114447.	13.7	24
102	T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. <i>Current Opinion in Oncology</i> , 2022, 34, 552-558.	2.4	17
103	Feasibility of in vivo CAR T cells tracking using streptavidin-biotin-paired positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	6.4	0
104	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. <i>Current Opinion in Critical Care</i> , 2022, 28, 540-550.	3.2	5
105	Reprogramming tumor-immune cell communication with a radiosensitive nanoregulator for immunotherapy. <i>Science China Materials</i> , 2023, 66, 352-362.	6.3	5
106	Identification of methylation signatures associated with CAR T cell in B-cell acute lymphoblastic leukemia and non-hodgkin's lymphoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
107	Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
108	Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. <i>Discover Oncology</i> , 2022, 13, .	2.1	13
109	Macrophages in melanoma: A double-edged sword and targeted therapy strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	9
110	CAR-T Therapy: A Promising Cancer Treatment. , 0, 8, 100-110.		0
111	Patch grafting of organoids of stem/progenitors into solid organs can correct genetic-based disease states. <i>Biomaterials</i> , 2022, 288, 121647.	11.4	7

#	ARTICLE	IF	CITATIONS
112	Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. <i>Radiotherapy and Oncology</i> , 2022, 175, 65-72.	0.6	13
113	CD137 (4-1BB) Signaling Drives a Tcr-Independent Exhaustion Program in CD8 T Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
114	Polarized Autologous Macrophages (PAM) Can Be a Tumor Vaccine. <i>Oncologie</i> , 2022, 24, 441-449.	0.7	6
115	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	97
116	Long Noncoding RNA LINC02249 Is a Prognostic Biomarker and Correlates with Immunosuppressive Microenvironment in Skin Cutaneous Melanoma. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	1.3	3
117	Gene Electrotransfer into Mammalian Cells Using Commercial Cell Culture Inserts with Porous Substrate. <i>Pharmaceutics</i> , 2022, 14, 1959.	4.5	4
118	The potential for treg-enhancing therapies in nervous system pathologies. <i>Clinical and Experimental Immunology</i> , 2023, 211, 108-121.	2.6	7
119	Technology meets TILs: Deciphering TÂcell function in the -omics era. <i>Cancer Cell</i> , 2023, 41, 41-57.	16.8	17
120	Natural cell based biomimetic cellular transformers for targeted therapy of digestive system cancer. <i>Theranostics</i> , 2022, 12, 7080-7107.	10.0	5
121	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1109-1125.	3.7	11
122	Cellular Senescence in Immunity against Infections. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11845.	4.1	11
124	Tumor buster - where will the CAR-T cell therapy "missile" go?. <i>Molecular Cancer</i> , 2022, 21, .	19.2	23
125	Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis. <i>Frontiers in Surgery</i> , 0, 9, .	1.4	4
126	High frequency of hyperglycaemia observed during <sc>CAR</sc> Tâcell treatment. <i>Diabetic Medicine</i> , 0, , .	2.3	0
127	Cellular immunotherapy for medulloblastoma. <i>Neuro-Oncology</i> , 2023, 25, 617-627.	1.2	7
128	Nanobody-based CAR T cells targeting intracellular tumor antigens. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113919.	5.6	7
129	Polymer- and lipid-based gene delivery technology for CAR T cell therapy. <i>Journal of Controlled Release</i> , 2023, 353, 196-215.	9.9	11
130	The signaling and the metabolic differences of various CAR T cell designs. <i>International Immunopharmacology</i> , 2023, 114, 109593.	3.8	2



#	ARTICLE	IF	CITATIONS
131	Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
132	High-Throughput and Efficient Intracellular Delivery Method via a Vibration-Assisted Nanoneedle/Microfluidic Composite System. <i>ACS Nano</i> , 2023, 17, 2101-2113.	14.6	6
133	Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. <i>Cells</i> , 2023, 12, 101.	4.1	0
134	Activation of cancer immunotherapy by nanomedicine. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
135	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	4.1	4
136	Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 176.e1-176.e8.	1.2	0
137	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. <i>European Journal of Cell Biology</i> , 2023, 102, 151284.	3.6	8
138	Diselenide-Based Dual-Responsive Prodrug as Pyroptosis Inducer Potentiates Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	11
139	Live-Cell Glycocalyx Engineering. <i>ChemBioChem</i> , 2023, 24, .	2.6	1
140	Cancer stem cell-immune cell collusion in immunotherapy. <i>International Journal of Cancer</i> , 2023, 153, 694-708.	5.1	1
141	Thermal immuno-nanomedicine in cancer. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 116-134.	27.6	60
142	Improved cancer immunotherapy strategies by nanomedicine. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	6.1	7
143	Multifunctional Nano-Biomaterials for Cancer Therapy via Inducing Enhanced Immunogenic Cell Death. <i>Small Methods</i> , 2023, 7, .	8.6	12
144	ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	1
145	Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2152.	4.1	4
146	Research Status of CAR-T Cell Immunotherapy in Tumor Treatment. <i>Journal of Biosciences and Medicines</i> , 2023, 11, 24-36.	0.2	0
147	Immunotherapy: Targeting Cancer Cells. <i>Biological and Medical Physics Series</i> , 2023, , 179-217.	0.4	0
148	CAR t-cell therapy in Bologna-Neurotoxicity Treatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study. <i>Journal of Neurology</i> , 2023, 270, 2659-2673.	3.6	5

#	ARTICLE	IF	CITATIONS
149	Genetically Programmable Vesicles for Enhancing CAR-T Therapy against Solid Tumors. <i>Advanced Materials</i> , 2023, 35, .	21.0	7
150	Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	2
151	CAR T-cells to treat brain tumors. <i>Brain Research Bulletin</i> , 2023, 196, 76-98.	3.0	7
152	Case report: Reversible punctate inflammatory foci in the corpus callosum: A novel radiological finding of CAR T-cell therapy-related neurotoxicity. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	2
154	A close look at current CAR-T cell immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	9
155	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	14
156	Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. <i>Cancer Research Communications</i> , 2023, 3, 640-658.	1.7	1
157	Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor. <i>Molecular Therapy - Oncolytics</i> , 2023, 29, 77-90.	4.4	1
158	Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma. <i>Functional and Integrative Genomics</i> , 2023, 23, .	3.5	0
159	Transformative Materials for Interfacial Drug Delivery. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	2
160	A Tetramethylpyrazine Releasing Hydrogel can Potentiate CAR-T Cell Therapy against Triple Negative Breast Cancer by Reprogramming Tumor Vasculatures. <i>Fundamental Research</i> , 2023, , .	3.3	1
161	Revealing the impact of CD70 expression on the manufacture and functions of CAR-T-cells based on single-cell transcriptomics. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3163-3174.	4.2	2
162	Combination of CAR-T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review). <i>Oncology Letters</i> , 2023, 26, .	1.8	5
163	Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
164	Immunotherapy in leukaemia. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 974-987.	2.0	1
165	Feasibility of an acoustophoresis-based system for a high-throughput cell washing: application to bioproduction. <i>Cytotherapy</i> , 2023, 25, 891-899.	0.7	1
166	Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. <i>Lancet Neurology</i> , The, 2023, 22, 578-590.	10.2	30
167	Are CAR T cells the answer to myasthenia gravis therapy?. <i>Lancet Neurology</i> , The, 2023, 22, 545-546.	10.2	1

#	ARTICLE	IF	CITATIONS
168	Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia. <i>Biomedicines</i> , 2023, 11, 1886.	3.2	1
169	Application of adoptive cell therapy in hepatocellular carcinoma. <i>Immunology</i> , 2023, 170, 453-469.	4.4	6
170	Exploration of cuprotoxicity-related genes for predicting prognosis and immunological characteristics in acute myeloid leukaemia based on genome and transcriptome. <i>Aging</i> , 2023, 15, 6467-6486.	3.1	0
171	Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment. <i>Current Medical Science</i> , 2023, 43, 631-646.	1.8	0
172	Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights. <i>Molecular Pharmaceutics</i> , 2023, 20, 5254-5277.	4.6	2
173	Pan-cancer analysis: <i>SPAG5</i> is an immunological and prognostic biomarker for multiple cancers. <i>FASEB Journal</i> , 2023, 37, .	0.5	0
174	Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review. <i>Journal of Personalized Medicine</i> , 2023, 13, 1261.	2.5	1
175	Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review. <i>Leukemia and Lymphoma</i> , 2023, 64, 1615-1633.	1.3	1
176	CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them. <i>HemaSphere</i> , 2023, 7, e937.	2.7	3
177	Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy. <i>Aging</i> , 2023, 15, 8664-8691.	3.1	1
178	Effectiveness and safety of <i>CD22</i> and <i>CD19</i> dual-targeting chimeric antigen receptor T cell therapy in patients with relapsed or refractory B cell malignancies: A meta-analysis. <i>Cancer Medicine</i> , 2023, 12, 18767-18785.	2.8	0
179	The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 1179-1191.	2.4	0
181	Exploring potential of exosomes drug delivery system in the treatment of cancer: Advances and prospective. <i>Medicine in Drug Discovery</i> , 2023, 20, 100163.	4.5	2
182	Targeting of tumor cells by custom antigen transfer: a novel approach for immunotherapy of cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
183	Application of exosomes as nanocarriers in cancer therapy. <i>Journal of Materials Chemistry B</i> , 0, , .	5.8	1
184	Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	1
185	Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, .	1.9	0
186	Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells. <i>Journal of Leukocyte Biology</i> , 0, , .	3.3	0

#	ARTICLE	IF	CITATIONS
187	17.ÂCancer. , 2023, , .		0
188	Regulation of telomerase towards tumor therapy. Cell and Bioscience, 2023, 13, .	4.8	0
189	Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas. Cancers, 2024, 16, 228.	3.7	0
190	NK cells as powerful therapeutic tool in cancer immunotherapy. Cellular Oncology (Dordrecht), 0, , .	4.4	0
191	SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. , 2024, 21, 213-226.		1
192	New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer Immunology, Immunotherapy, 2024, 73, .	4.2	0
193	Non-viral delivery of RNA for therapeutic T cell engineering. Advanced Drug Delivery Reviews, 2024, 208, 115215.	13.7	0
194	Multi-omics analysis of TLCD1 as a promising biomarker in pan-cancer. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	0
196	Immunotherapeutics: Advancing precision medicine in cancer treatment. IP International Journal of Comprehensive and Advanced Pharmacology, 2024, 9, 17-23.	0.3	0
197	PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma. European Journal of Medical Research, 2024, 29, .	2.2	0
198	Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation. Journal of Inflammation Research, 0, Volume 17, 1805-1820.	3.5	0
199	Combination of theoretical analysis and experiments: Exploring the role of PLA2G7 in human cancers, including renal cancer. Heliyon, 2024, 10, e27906.	3.2	0
200	Novel CAR-T cells targeting TRKB for the treatment of solid cancer. Apoptosis: an International Journal on Programmed Cell Death, 0, , .	4.9	0
201	Adoptive T-Cell Therapy for the Treatment of Lung Cancer. , 2024, , 101-130.		0
202	Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy. Neurological Sciences, 0, , .	1.9	0
204	Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell International, 2024, 24, .	4.1	0